Aravive Inc

Aravive — Investor Presentation (November 2020)

45 slides from Aravive's investor presentation, Nov 19, 2020

  1. Slide 1: Corporate Presentation November 2020

    © 2020 Aravive, Inc. Corporate Presentation November 2020 Halting Disease Progression in its Tracks ARAV (NASDAQ) Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    © 2020 Aravive, Inc. Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally i

  3. Slide 3: Aravive Senior Management and Board of Directors

    © 2020 Aravive, Inc. Aravive Senior Management and Board of Directors Board of Directors Senior Management Gail McIntyre, Ph.D., DABT CEO Reshma Rangwala, M.D., Ph.D. CMO Fred Eshelman, Pharm D. Chairman of the Board Amato Giaccia, Ph.D. Director Michael Rogers Director Gail McIntyre, Ph.D., DABT Di

  4. Slide 4: Aravive Top Shareholders

    © 2020 Aravive, Inc. | CONFIDENTIAL Aravive Top Shareholders Insiders, Institutional Shareholders Make Up >70% of Our Outstanding Shares % Ownership** 24.3% % of Shares Held by Insiders 46.3% % of Shares Held by Institutional Investors* * As per SEC filings – 13D, 13F, 13G, Forms 3 and Form 4, Proxy

  5. Slide 5: Serious Cancers High Unmet Medical Need

    © 2020 Aravive, Inc. Serious Cancers High Unmet Medical Need Clinical Programs Focused on Tumors That Express GAS6/AXL Company Focus

  6. Slide 6: Uniquely Focused on GAS6/AXL Signaling Pathway

    GAS6 and AXL are overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival GAS6 is growth factor that regulates several biologic processes in cells through interaction with its receptors, including AXL, Tyro3, and Mer GAS6 is the sole acti

  7. Slide 7: GAS6 and/or AXL Expression Is Associated with Poor Survival in Many Cancers

    © 2020 Aravive, Inc. GAS6 and/or AXL Expression Is Associated with Poor Survival in Many Cancers Tumor Type AXL Tumor Expression1 Ovarian >70% Hao et al. 2017. AXL is highly expressed in ovary-derived tumors and is a prognostic gene in ovarian cancer. Rankin et al 2010. 73% of all ovarian tumor samp

  8. Slide 8: Engineered Decoy Receptor is Preferred Approach for GAS6/AXL Inhibition

    © 2020 Aravive, Inc. COMPANY DRUG (STAGE) TARGET SELECTIVE FOR AXL ARAVIVE AVB-500 (Ph Ib/II) GAS6 YES Astellas gilteritinib (Market; AML) AXL (Multi-kinase) NO Exelixis cabozantinib (Market; RCC & HCC) AXL (Multi-kinase) NO Mirati (BeiGene) sitravatinib (Ph III) AXL (Multi-kinase) NO Lilly merestin

  9. Slide 9: AVB-500: First- and Potential Best-In-Class Opportunity in Oncology

    © 2020 Aravive, Inc. AVB-500: First- and Potential Best-In-Class Opportunity in Oncology Ultra-high affinity decoy protein that targets the GAS6/AXL signaling pathway Neutralizes GAS6 , starving tumors of signal that promotes growth, invasion, and metastasis Well-tolerated , with no unexpected dose-

  10. Slide 10: Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer

    © 2020 Aravive, Inc. Platinum Resistant Ovarian Cancer (PROC) Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC) 5th LEADING CAUSE OF DEATH among women in the U.S. (Ovarian Cancer) ~70% OF PATIENTS are diagnosed with advanced disease 50% 5-YEAR relative survival (9-12 months PROC) LES

  11. Slide 11: AVB-500 in PROC: Phase 1a and 1b PK/PD Summary Data

    AVB-500 follows target-mediated drug disposition (TMDD) kinetics, consistent with other Fc proteins and antibodies. Used a model-informed drug development approach (MIDD) to identify RP2D; PK/PD translated from pre-clinical to clinical. Exposure response (E-R) analysis demonstrated that subjects wit

  12. Slide 12: Phase 1b Trial Design in PROC

    © 2020 Aravive, Inc. AVB-500 (AVB): q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 of 28-day cycle; Paclitaxel (PAC) 80 mg/m2 day 1, day 8, day 15 of 28-day cycle Maintenance dosing on AVB-500 monotherapy AVB 500 10 mg/kg + PLD (N=21) AVB 500 15 mg/kg + PLD (N=2) Select RP2D AVB 500 10 m

  13. Slide 13: Phase 1b Efficacy Data for Patients Above MEC

    © 2020 Aravive, Inc. Efficacy Data for 10mg/kg and 15mg/kg Patients: >MEC PAC (N=10) PLD (N=14) mPFS (months) 7.5 3.7 ORR 5 (50%) [2 CRs^ (20%)] 2 (14%) mDoR (months) 7.4 5.3 mOS (months)* 19.0 12.7 Phase 1b Trial: Efficacy Data for Patients with Greater Than MEC (10mg/kg and 15mg/kg Patients) MEC =

  14. Slide 14: AVB-500 + PAC and Prior Bev Use

    © 2020 Aravive, Inc. AVB-500 + PAC and Prior Bev Use for 10mg/kg and 15mg/kg Patients Bev Naïve (n=9) Previous Bev (n=10) mPFS (months) 7.7 2.8 ORR 6 (67%) [2 CRs^ (22%)] 1 (10%) mDoR (months) 7.2 3.7 mOS (months)* 19.3 9.2 Phase 1b Trial: Efficacy Data AVB-500 + PAC and Prior Bevacizumab Use 10mg/k

  15. Slide 15: Potential Biomarker: Serum sAXL/GAS6 Ratio

    © 2020 Aravive, Inc. Potential Biomarker: Serum Levels of sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo sAXL/GAS6 >0.773 AVB-500 + PAC (10 and 15 mg/kg patients) Yes (>0.773) NO N 11 7 CR 2 (18%) 0 PR 4 (36%) 0 ORR 6 (55%) 0 SD 3 (27%) 4 (57%) CBR 9 (82%) 4 (57%) PD 2 (18%) 3 (43%) 55%

  16. Slide 16: mPFS by Biomarker and Prior Bevacizumab Use

    © 2020 Aravive, Inc. mPFS for 10 and 15 mg/kg PAC Groups by Biomarker and Prior Bevacizumab Use AVB-500 + PAC sAXL/GAS6 >0.773 Yes No Yes No BEV NAÏVE PREV BEV N 6 2 5 5 mPFS (months) 8.4 2.7 2.8 2.9 Probability

  17. Slide 17: mOS by Biomarker and Prior Bevacizumab Use

    © 2020 Aravive, Inc. mOS for 10 and 15 mg/kg PAC Groups by Biomarker and Prior Bevacizumab Use AVB-500 + PAC sAXL/GAS6 >0.773 Yes No Yes No BEV NAIVE PREV BEV N 6 2 2 5 5 mOS* (months) Not eval (Lower 95% CI = 19.3) 8.5 8.5 9.2 9.2 *Study ongoing so data can change

  18. Slide 18: Clinical Response in Patients with <3 Month PFI

    CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PFI PER KOBAYASHI-KATO ET AL, 2019 (N=21) CLINICAL RESPONSE OF AVB-500+CHEMO IN PATIENTS WITH <3MO PFI ORR= objective response rate; SD=stable disease; CBR=clinical benefit rate; PD=progressive disease; PFI=platinum-free interval 12 patients in

  19. Slide 19: Clinical Response in 3L and 4L

    CLINICAL RESPONSE OF AVB-500+CHEMO IN 3L AND 4L CLINICAL RESPONSE OF CHEMOTHERAPY IN 3L AND 4L PER BRUCHIM ET AL, 2013 (N=99) 20 patients in the high exposure AVB-500+chemo group; Two CRs in High Exposure Category Updated Analysis for High-Exposure Patients (>MEC) ORR= objective response rate; SD=st

  20. Slide 20: Strong Safety Profile of AVB-500

    Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the concomitant treatment (PAC or PLD) and th

  21. Slide 21: Selected 15mg/kg Dose for AVB-500 Phase 3

    © 2020 Aravive, Inc. Consistent with hypothesis that trough levels are associated with clinical activity, all 5 evaluable patients in 15 mg/kg cohort achieved MEC by their first CT scan, following four doses of AVB-500. Updated modeling using all patient data suggest that at 15mg/kg, pharmacokinetic

  22. Slide 22: Conclusions and Recommendations for Phase 3 Registrational Trial in PROC

    Conclusions and Recommendations for Phase 3 Registrational Trial in PROC Clinical activity of AVB-500 plus chemo was more pronounced in bev naïve patients P3 trial will stratify by previous bev use and interim analyses in a robust setting will allow us to interrogate magnitude of AVB-500 benefit in

  23. Slide 23: AVB-500 Phase 3 Adaptive Registrational Trial Design in PROC

    Potential Registrational Study Primary objective to assess anti-tumor activity of AVB-500 in combination with PAC as measured by PFS Secondary endpoints: OS, ORR based on RECIST 1.1, DOR, QoL, CBR, PK/PD Patients with high-grade serous ovarian cancer only; stratified by prior bevacizumab use, ECOG,

  24. Slide 24: AVB-500 Competitive Advantage in PROC

    Potential Registrational Study © 2020 Aravive, Inc. AVB-500 Competitive Advantage in PROC Potentially More Favorable Benefit/Risk Profile and Well-Positioned for 1L Favorable Safety Profile to Date NO DLTs like chemotherapies and ADCs NO dose reductions or discontinuations to manage toxicities Admin

  25. Slide 25: Other Studies in PROC

    Potential Registrational Study © 2020 Aravive, Inc. Other Studies in PROC AVB-500 + PAC >MEC N=10 XMT-1536 N=47 Mirvetuximab soravtansine N=248 ITT = 366 Tumor Type Ovarian (80%) 1o peritoneal (20%) Ovarian (72%) Fallopian Tube (15%) 1o peritoneal (13%) Ovarian (83%) Fallopian Tube (6%) 1o peritonea

  26. Slide 26: AVB-500 Competitive Advantage in PROC: Benefit/Risk Profile

    Potential Registrational Study © 2020 Aravive, Inc. AVB-500 Competitive Advantage in PROC Potentially More Favorable Benefit/Risk Profile AVB-500 + PAC 10/15mg/kg >MEC XMT-1536, higher NaPi2b/ALL Mirvetuximab soravtansine, ITT FRα-positive N 10 20/29 366 (2:1 R) ORR 5 (50%) [3 PRs (30%); 2 CRs (20%)

  27. Slide 27: Current Oncology Pipeline: ccRCC

    © 2020 Aravive, Inc. Current Oncology Pipeline: ccRCC Clear Cell Renal Cell Carcinoma (ccRCC) 15% 70k RESISTANCE To CHEMO OVER LESS THAN 5-YEAR relative survival for metastatic renal cancer NEW CASES expected in the U.S. in 2020 Is Common

  28. Slide 28: Strong biological rationale for ccRCC

    © 2020 Aravive, Inc. Current Oncology Pipeline: Clear Cell Renal Carcinoma (ccRCC) Strong biological rationale for clear cell Renal Cell Carcinoma (ccRCC)1 VHL tumor suppressor gene mutated in at least 80%, causes increase in AXL AXL/GAS6 levels predict prognosis and survival in human1 Strong in viv

  29. Slide 29: Single Agent Efficacy in Highly Metastatic Renal Model

    © 2020 Aravive, Inc. Single Agent Efficacy in Highly Metastatic Renal Model (SN12L1) 5mg/kg AXL decoy administered twice/wk 10 mg/kg administered QOD AVB-S6 Rankin et al, PNAS, September 16, 2014, vol. 111, no. 37, 13373–13378 Note: S6-1 and AVB-S6 are related AXL decoy proteins; both in S6 family

  30. Slide 30: AVB-500 and TKI Combination in TKI-Resistant Renal PDX

    © 2020 Aravive, Inc. AVB-500 and TKI Combination Significantly Reduced Growth Rate in TKI-Resistant Renal PDX Xiao et al, Cancer Res 2019;79:5758–68 AVB-S6 is AVB-500 Control Pazopanib AVB-S6 AVB-S6+Pazopanib Control Pazopanib AVB-S6 AVB-S6+Pazopanib

  31. Slide 31: AVB-500 Phase 1b / Phase 2 Trial Design in ccRCC

    Phase 1b Trial of AVB-500 in Combination with Cabozantinib Up to 18 patients; ability to increase/decrease dose based on tolerability, PK/PD On track to initiate end 2020 Phase 2 Controlled, Randomized Trial Primary endpoint: mPFS Secondary endpoints: ORR, mDoR, CBR, and mOS Histologically confirmed

  32. Slide 32: ccRCC Competitive Treatment Landscape

    © 2020 Aravive, Inc. ccRCC Competitive Treatment Landscape NCCN guidelines preferred regimens include cabozantinib, nivolumab (both category 1). However, there are various other treatment options available in the relapsed ccRCC treatment landscape including Inlyta (category 1), Afinitor, or the comb

  33. Slide 33: Market Opportunity: PROC and ccRCC Indications

    © 2020 Aravive, Inc. | CONFIDENTIAL Market Opportunity – AVB-500: PROC and ccRCC Indications Addressable Market PROC1 ccRCC2 US EU5 US EU5 Estimated Patient Population ~12K ~11K ~9K ~9K 2L-4L platinum-resistant ovarian cancer (PROC), high grade serous patients 2L advanced/metastatic clear cell renal

  34. Slide 34: AVB-500 Development Strategy: Basket Trial Concepts

    © 2020 Aravive, Inc. AVB-500 Development Strategy: Basket Trial Concepts To Efficiently Expand Pipeline Efficiently expands the number of unique tumor types in which AVB-500 in combination is being evaluated and expands the AVB-500 treated market Combines with agents that are currently embedded as S

  35. Slide 35: Potential Trials: AVB-500 + PARP and PD1 Basket Trials

    Potential Registrational Study © 2020 Aravive, Inc. Potential Trials: AVB-500 + PARP and AVB-500 + PD1 Basket Trials Phase 1b/2 Basket Trial of AVB-500 + PARP Inhibitor Potential indications: HER- breast cancer, pancreas, uterine, ovarian (1L maintenance) Preclinical data shows AVB-500 induces a “BR

  36. Slide 36: Market Opportunity: Breast, Pancreatic, NSCLC, and Bladder Indications

    © 2020 Aravive, Inc. | CONFIDENTIAL Market Opportunity – AVB-500: Breast, Pancreatic, NSCLC, and Bladder Indications Addressable Market Breast1 Pancreatic2 NSCLC3 Bladder4 US EU5 US EU5 US EU5 US EU5 Estimated Patient Population ~90K ~100K ~28K ~28K ~36K ~39K ~16K ~29K HER2 negative 2L+ patients (in

  37. Slide 37: Current Oncology Pipeline

    © 2020 Aravive, Inc. Indication Preclinical 3rd Oncology Phase 1 Phase 3 Phase 2 Phase 2a Phase 2b Anti-CTGF AVB-500 IST with AstraZeneca Phase 1b complete; plan to initiate Phase 3 trial in Q121 OVARIAN CANCER platinum resistant (PAC or PLD combination) Recruiting OVARIAN CANCER platinum resistant

  38. Slide 38: WuXi Biologics Collaboration: Anti-CTGF for Cancer and Fibrosis

    © 2020 Aravive, Inc Objective: Identify/develop novel high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), implicated in cancer and fibrosis and identified from a similar target discovery screen that identified the significance of the GAS6/AXL pathw

  39. Slide 39: Potential Indications for Anti-CTGF Include Cancer and Fibrosis

    Summary of Program Attributes Potential Indications for Anti-CTGF Include Cancer and Fibrosis Pancreatic Cancer and CTGF Lipson et al. Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S24 Pancreatic ductal adenocarcinoma (PDAC) is the fourth most frequent cause of cancer-related deaths worldwide with a

  40. Slide 40: Aravive and 3D Medicines Collaboration in Greater China

    © 2020 Aravive, Inc. Aravive and 3D Medicines Collaboration to Develop and Commercialize AVB-500 in Greater China Exclusive collaboration and license agreement for the development and commercialization of AVB-500 across all oncology indications in mainland China, Hong Kong, Macau, and Taiwan (Greate

  41. Slide 41: Development Milestones and Data Flow

    ccRCC P2 Data Flow, Assuming 2 New P1b/P2 Oncology Programs, 1 Discovery Program and 4 ISTs Development Milestones and Data Flow PROC P3 FDA feedback received Submit BLA 2H21 1H21 1H22 2H22 1H24 2H23 1H23 2H20 IST Bladder Avelumab combination (EMD Serono) PROC ccRCC P1b ccRCC IST PROC Durva combinat

  42. Slide 42: Aravive Deep Oncology Pipeline and Strategy: Following the Science

    Data Flow, Assuming 2 New P1b/P2 Oncology Programs, 1 Discovery Program and 4 ISTs Aravive Deep Oncology Pipeline and Strategy: Following the Science HIGH UNMET NEED STRONG BIOLOGIC RATIONALE EXPAND TO OTHER CANCERS and/or BROADER PATIENT POPULATIONS HER- Breast Cancer Pancreatic NSCLC PROC Potentia

  43. Slide 43: Cash Runway

    Data Flow, Assuming 2 New P1b/P2 Oncology Programs, 1 Discovery Program and 4 ISTs Cash Runway EXPAND TO OTHER CANCERS and/or BROADER PATIENT POPULATIONS HER- Breast Cancer Pancreatic NSCLC PROC Potential to combine with PARPi, bevacizumab and use 1L neoadjuvant TNBC Head and Neck Bile Duct Cancer L

  44. Slide 44: Positioned for Long-Term Growth

    Q4 2020 P1b/P2 ccRCC initiation at 15 mg/kg Note: Above milestones may be impacted by COVID-19 © 2020 Aravive, Inc. Q1 2021 P3 PROC initiation at 15 mg/kg Q1 2022 P3 PROC interim analysis GROWTH DRIVERS Pipeline Expansion in Oncology Global Business Development Opportunities Investigator Sponsored T

  45. Slide 45: Thank You!

    © 2020 Aravive, Inc. Thank You! Halting Disease Progression in its Tracks

Aravive — Investor Presentation (November 2020) on 6ix